2023
An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrials
2021
Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis
Oomen P, Begemann M, Brand B, de Haan L, Veling W, Koops S, van Os J, Smit F, Bakker P, van Beveren N, Boonstra N, Gülöksüz S, Kikkert M, Lokkerbol J, Marcelis M, Rosema B, de Beer F, Gangadin S, Geraets C, van ‘t Hag E, Haveman Y, van der Heijden I, Voppel A, Willemse E, van Amelsvoort T, Bak M, Batalla A, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering R, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Veen N, Veerman S, Wiersma S, Graveland E, Hoornaar J, Sommer I. Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. Psychological Medicine 2021, 53: 2317-2327. PMID: 34664546, PMCID: PMC10123843, DOI: 10.1017/s0033291721004153.Peer-Reviewed Original ResearchConceptsDistinct cognitive subgroupsCognitive subgroupsFirst-episode psychosisDiscrete cognitive profilesGeneral functioningTrend-level effectsCognitive profileSelf-reported functional outcomesCognitive clustersCognitive deficitsCognitionBrief assessmentFunctional outcomeLarge sampleFEP patientsClinical outcomesCurrent resultsSevere clinical symptomsPsychosisEarly identificationHealthy controlsCluster analysisClinical symptomsFunctioningDeficits
2020
S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS
Bor E, Quattrone D, Rodriguez V, Alameda L, Guloksuz S, Murray R. S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin 2020, 46: s78-s78. PMCID: PMC7234345, DOI: 10.1093/schbul/sbaa031.181.Peer-Reviewed Original ResearchLength of hospitalisationCase-control studyClinical outcomesFunctional outcomeClinical utilityDepressive symptomsSymptom dimensionsPositive symptomsNegative symptomsGlobal functioningFirst-episode psychosis patientsMulticentre case-control studyBaseline positive symptomsLong-Term ClinicalRisk of hospitalisationEpisode psychosis patientsPoor clinical outcomeFirst-episode psychosisCurrent clinical utilityPotential clinical utilitySymptom-based approachFurther outcome researchHospital admissionBetter prognosisProspective study
2017
A critique of the “ultra‐high risk” and “transition” paradigm
van Os J, Guloksuz S. A critique of the “ultra‐high risk” and “transition” paradigm. World Psychiatry 2017, 16: 200-206. PMID: 28498576, PMCID: PMC5428198, DOI: 10.1002/wps.20423.Peer-Reviewed Original ResearchClinical high riskUltra-high riskCommon mental disordersMental disordersPsychotic experiencesCHR researchHigh-risk approachMental health problemsPublic health perspectiveFalse-positive findingsTransdiagnostic expressionClinical picturePoor outcomePoor prognosisFunctional outcomeBaseline differencesHigh riskOmega-3Health problemsPositive findingsEpidemiological researchDiagnostic shiftUHR sampleYoung individualsHealth perspective